Agilus Diagnostics unveils Illumina NovaSeq X to revolutionize multi‑omic capabilities and genomic testing in India

▴ Agilus Diagnostics
One of India’s most advanced genomic sequencing platforms, NovaSeq X will accelerate early diagnosis and elevate precision diagnostics nationwide.

National, January 29, 2026: Agilus Diagnostics, one of India’s largest diagnostic networks and a subsidiary of Fortis Healthcare Ltd., today announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory—strengthening India’s capacity for next‑generation sequencing at scale. The launch was attended by Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, Dr. Anand K., Managing Director & CEO, Agilus Diagnostics Ltd., and Mr. Deepak Narang, Chief Operating Officer, Agilus Diagnostics.

Genomic technologies are transforming healthcare by enabling earlier diagnosis and more precise insights into complex diseases. Sequencing today supports a wide range of applications—from rare and inherited disorders to reproductive health, pharmacogenomics, infectious disease surveillance, and large‑scale genome programs.

The NovaSeq X strengthens Agilus Diagnostics’ molecular testing capabilities through high‑throughput sequencing and scalable analytics. Its multi‑omic capacity delivers rapid, high‑resolution results across diverse clinical needs. Through Agilus’ nationwide network, these advanced capabilities become accessible to clinicians and patients in both metro and emerging markets.

Powered by high‑density flow cells and automation, the NovaSeq X enables whole exome sequencing (WES), whole genome sequencing (WGS), and multi‑omic analysis with exceptional speed and accuracy. Deployed for high‑fidelity clinical decision‑making—not just research—it provides physicians with actionable molecular insights and faster turnaround times.

Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High‑quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalized and preventive care. Agilus’ investment brings cutting‑edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions.”

Speaking at the launch, Dr. Anand K., Managing Director & CEO, Agilus Diagnostics, added, “The NovaSeq X marks a major step in our precision diagnostics journey. It strengthens our multi‑omic capabilities across genomics and proteomics, enabling faster, high‑resolution insights that power personalised medicine. This advancement brings us closer to delivering truly predictive and individualized care for patients across India.”

For clinicians and researchers, the enhanced capacity translates into:

  • Whole exome and whole genome testing for comprehensive variant detection
  • Genetic evaluation of inherited and rare disorders
  • Reproductive and maternal health applications, including carrier screening and prenatal testing
  • Pharmacogenomic assessments to inform drug response and dosing
  • Infectious disease sequencing for pathogen tracking and antimicrobial resistance insights
  • Liquid biopsy (ctDNA) analysis and multi‑omic studies for longitudinal disease monitoring and deeper biological understanding

The platform powers Agilus’ expanding portfolio of advanced assays, including proprietary liquid biopsy panels, rare disease testing workflows, reproductive genomics, pharmacogenomic profiling, infectious disease sequencing, and multi‑omic studies. By integrating these outputs into established clinical pathways, Agilus converts complex molecular data into clear and actionable reports for clinicians.

This investment accelerates Agilus Diagnostics’ vision for precision diagnostics and predictive healthcare in India. The NovaSeq X positions Agilus among the few providers ready for future‑focused precision medicine—encompassing population genomics, proteomic innovation, and longitudinal patient monitoring—while ensuring next‑generation diagnostics remain scalable, clinically meaningful, and accessible nationwide.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026